Saccharin

Saccharin

SCHEMBL514398

O=C1NS(=O)(=O)c2ccccc21.O=C1NS(=O)(=O)c2ccccc21.[NaH]

nearest known ligand 0.96

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 7/20 0.96
CA9 Q16790 7/20 0.96
CA2 P00918 5/20 0.96
CA1 P00915 4/20 0.96
CA7 P43166 3/20 0.96
KDM4E B2RXH2 3/20 0.96
CA4 P22748 2/20 0.96
USP2 O75604 1/20 0.96
LMNA P02545 1/20 0.96
BCHE P06276 1/20 0.96
CA6 P23280 1/20 0.96
CA5A P35218 1/20 0.96
KMT2A Q03164 1/20 0.96
CA14 Q9ULX7 1/20 0.96
CA5B Q9Y2D0 1/20 0.96
ALDH1A1 P00352 3/20 0.58
RET P07949 2/20 0.53
GRK5 P34947 2/20 0.53
TYRO3 Q06418 2/20 0.53
DYRK1B Q9Y463 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Saccharin SCHEMBL3373 1.00 CA12 (0.96) CA12CA9CA2CA1CA7
Saccharin SCHEMBL10627242 1.00 CA12 (0.96) CA12CA9CA2CA1CA7
Saccharin SCHEMBL3374 1.00 CA12 (0.96) CA12CA9CA2CA1CA7
Saccharin SCHEMBL8802065 1.00 CA12 (0.96) CA12CA9CA2CA1CA7
Saccharin SCHEMBL10899217 1.00 CA12 (0.96) CA12CA9CA2CA1CA7
Saccharin SCHEMBL11399526 1.00 CA12 (0.96) CA12CA9CA2CA1CA7
Saccharin SCHEMBL4624412 1.00 CA12 (0.96) CA12CA9CA2CA1CA7
Saccharin SCHEMBL9463482 1.00 CA12 (0.96) CA12CA9CA2CA1CA7
Saccharin SCHEMBL9463164 1.00 CA12 (0.96) CA12CA9CA2CA1CA7
Saccharin SCHEMBL8214948 1.00 CA12 (0.96) CA12CA9CA2CA1CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117638200-B Lithium ion battery and electronic device 宁德新能源科技有限公司 2024-04-30 CN claimed
CN-117638200-A Lithium ion battery and electronic device 宁德新能源科技有限公司 2024-03-01 CN claimed
EP-3141239-B1 FRAGRANCE COMPOSITIONS AND USES THEREOF PROCTER & GAMBLE (US) 2023-05-10 EP claimed
EP-2780748-B1 A SILICONE HYDROGEL LENS WITH A CROSSLINKED HYDROPHILIC COATING NOVARTIS AG (CH) 2016-01-13 EP claimed
EP-2718751-B1 SILICONE HYDROGEL LENSES WITH NANO-TEXTURED SURFACES NOVARTIS AG (CH) 2015-07-22 EP claimed
EP-2780748-A1 A SILICONE HYDROGEL LENS WITH A CROSSLINKED HYDROPHILIC COATING Novartis AG (CH) 2014-09-24 EP claimed
EP-2718751-A1 SILICONE HYDROGEL LENSES WITH NANO-TEXTURED SURFACES Novartis AG (CH) 2014-04-16 EP claimed
WO-2013074535-A1 A SILICONE HYDROGEL LENS WITH A CROSSLINKED HYDROPHILIC COATING NOVARTIS AG (CH) 2013-05-23 WO claimed
WO-2012170603-A1 SILICONE HYDROGEL LENSES WITH NANO-TEXTURED SURFACES NOVARTIS AG (CH) 2012-12-13 WO claimed
EP-4396617-A1 A METHOD FOR PRODUCING WETTABLE SILICONE HYDROGEL CONTACT LENSES Alcon Inc. (CH) 2024-07-10 EP disclosed
EP-3724696-B1 WEEKLY AND MONTHLY DISPOSABLE WATER GRADIENT CONTACT LENSES ALCON INC (CH) 2024-07-03 EP disclosed
US-20240176047-A1 WEEKLY AND MONTHLY DISPOSABLE WATER GRADIENT CONTACT LENSES ALCON INC. (CH) 2024-05-30 US disclosed
EP-2705808-B1 Silicone hydrogel lenses with water-rich surfaces ALCON INC (CH) 2024-05-01 EP disclosed
CN-117638200-B Lithium ion battery and electronic device 宁德新能源科技有限公司 2024-04-30 CN disclosed
EP-1363580-A2 COMPOSITIONS HAVING ANTI-DENTAL CARIES FUNCTION Ezaki Glico Co., Ltd. (JP) 2003-11-26 EP disclosed
US-20030087875-A1 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations IVAX RESEARCH HOLDINGS, INC. 2003-05-08 US disclosed
WO-2003020735-A1 SACCHARIDE SULFATION METHODS IVAX RESEARCH, INC. (US) 2003-03-13 WO disclosed
WO-2002083700-A2 HYPERSULFATED DISACCHARIDES AND METHODS OF USING THE SAME FOR THE TREATMENT OF INFLAMMATIONS IVAX RESEARCH, INC. (US) 2002-10-24 WO disclosed
WO-2002067871-A2 COMPOSITIONS HAVING ANTI-DENTAL CARIES FUNCTION EZAKI GLICO CO., LTD. (JP) 2002-09-06 WO disclosed
CN-1192673-A Composition and method for remineralization of teeth ENAMELON INC (US) 1998-09-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087875-A1 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations IL5, LTC4S, CD44 CA12 457/4885CA9 651/4885CA2 844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.